Koru Medical Systems (KRMD) late Thursday disclosed plans to begin a late-stage trial for a new indication of an existing commercialized drug therapy through a collaboration with an unnamed pharmaceutical manufacturer to evaluate the safety, efficacy and performance of the drug for treating patients with a rare renal disorder following kidney transplants.
Koru shares recently were climbing about 1% in extended session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.